Explore how BTK resistance drives poor outcomes in relapsed mantle cell lymphoma and why ZUMA-2 CAR T therapy emerges as a ...
As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides commentary on frequently asked questions. The European Medicines Agency’s ...
Dr Nabil Saba emphasizes that while systemic therapy has revolutionized the treatment of anaplastic thyroid cancer (ATC), ...
LYT-200 plus HMA at 12 mg/kg delivered 45.5% ORR in 11 R/R HR-MDS patients, including 27.3% CRs, despite 100% prior HMA ...
Rashmi Chugh, MD, discusses the early outcomes of a trial of ozekibart plus chemotherapy in Ewing sarcoma. Rashmi Chugh, MD, ...
Dr Singh also takes viewers inside the critical—and often underappreciated—role of multidisciplinary collaboration, ...
Early-line data appears encouraging, with MajesTEC-3 complemented by emerging newly diagnosed data showing near-universal ...
The FDA review of the biologics license application includes data on SC isatuximab as both manual injection and via an ...
The evolving treatment landscape in polycythemia vera (PV) is shifting from a focus on hematocrit control to a more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results